Literature DB >> 19465705

The prevalence and natural history of hepatitis B in the 21st century.

William D Carey1.   

Abstract

The prevalence of chronic hepatitis B virus (HBV) infection varies by geographic region. Most of North America is a low-prevalence (< 2%) area. Certain high-prevalence pockets exist, especially areas with a high proportion of Asian immigrants and Alaskan and northern Canadian native populations, where rates of chronic HBV are as high as 5% to 15%. In most low-prevalence areas, HBV infection is acquired mainly during adolescence and midadulthood, whereas perinatal transmission is the main route in high-prevalence (> or = 8%) areas. Up to 40% of patients with chronic HBV infection develop liver complications. Age at acquisition affects the likelihood of chronicity and the development of liver complications. The risk of each is greatest with perinatal transmission; the disease is usually self-limiting when exposure to HBV occurs during adolescence or young adulthood. Viral load predicts progression to cirrhosis and hepatocellular carcinoma; therefore, reducing viral load is the major goal of treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465705     DOI: 10.3949/ccjm.76.s3.01

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  12 in total

1.  Knowledge, Awareness and Medical Practice of Asian Americans/Pacific Islanders on Chronic Hepatitis B Infection: Review of Current Psychosocial Evidence.

Authors:  ThuyQuynh N Do; Sanggon Nam
Journal:  Pogon Sahoe Yongu       Date:  2011

2.  Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Robert L Kruse; Jennifer R Kramer; Gia L Tyson; Zhigang Duan; Liang Chen; Hashem B El-Serag; Fasiha Kanwal
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

3.  Estimating the prevalence of chronic hepatitis B virus infection--New York City, 2008.

Authors:  Anne Marie France; Katherine Bornschlegel; Julie Lazaroff; Joseph Kennedy; Sharon Balter
Journal:  J Urban Health       Date:  2012-04       Impact factor: 3.671

4.  The healthcare burden imposed by liver disease in aging Baby Boomers.

Authors:  Gary L Davis; William L Roberts
Journal:  Curr Gastroenterol Rep       Date:  2010-02

5.  Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donor.

Authors:  Chang-Zheng Li; Zhong-Kun Liang; Zhen-Rui Chen; Hai-Bo Lou; Ye Zhou; Zhe-Huan Zhang; Fei Yu; Shuwen Liu; Yuanping Zhou; Shuguang Wu; Wenling Zheng; Wanlong Tan; Shibo Jiang; Chen Zhou
Journal:  Cell Mol Immunol       Date:  2011-12-19       Impact factor: 11.530

6.  Hepatitis B knowledge, screening, and vaccination among Hmong Americans.

Authors:  Jennifer Kue; Sheryl Thorburn
Journal:  J Health Care Poor Underserved       Date:  2013-05

Review 7.  Hepatitis B virus lineages in mammalian hosts: potential for bidirectional cross-species transmission.

Authors:  Cibele R Bonvicino; Miguel A Moreira; Marcelo A Soares
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

8.  Prevalence of hepatitis B virus (HBV) infection among Hmong immigrants in the San Joaquin Valley.

Authors:  Muhammad Y Sheikh; Mouatou Mouanoutoua; Matthew D Walvick; Leepao Khang; Jasjit Singh; Steven Stoltz; Paul K Mills
Journal:  J Community Health       Date:  2011-02

9.  Prevalence of hepatitis d virus infection among patients with chronic hepatitis B attending birjand hepatitis clinic (East of iran) in 2012.

Authors:  Masood Ziaee; Ghodsieh Azarkar
Journal:  Hepat Mon       Date:  2013-08-25       Impact factor: 0.660

10.  Association between IL-18 polymorphisms, serum levels, and HBV-related hepatocellular carcinoma in a Chinese population: a retrospective case-control study.

Authors:  Jingui Bao; Yu Lu; Yan Deng; Chengzhi Rong; Yanqiong Liu; Xiuli Huang; Liuying Song; Shan Li; Xue Qin
Journal:  Cancer Cell Int       Date:  2015-07-25       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.